Skip to main content
. 2023 Apr 17;9(2):00639-2022. doi: 10.1183/23120541.00639-2022

FIGURE 2.

FIGURE 2

Changes in daily doses of inhalation steroid budesonide after 12 months of observation. Group A: omalizumab+placebo; Group B: SCIT-HDM+omalizumab; Group C: SCIT-HDM+placebo. *: significant decrease (Chi-square test) for p=0.029; **: significant decrease for p=0.015.